RFM
vs
D
DAX Index
RFM
Over the past 12 months, RFM has underperformed DAX Index, delivering a return of -48% compared to the DAX Index's +10% growth.
Stocks Performance
RFM vs DAX Index
Performance Gap
RFM vs DAX Index
Performance By Year
RFM vs DAX Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Sensorion SA
Glance View
Sensorion SAS is a biopharmaceutical company, which engages in the development of therapies to treat and prevent diseases of the inner ear such as deafness, vertigo and tinnitus. The company is headquartered in Montpellier, Occitanie and currently employs 34 full-time employees. The company went IPO on 2015-04-21. The firm is principally active in the development of targeted therapeutic solutions to treat inner ear diseases. The firm develops also drug treatments, from molecular biology all the way to animal pharmacology, toxicology, and clinical research and therapeutic solutions to treat vestibular deficits. Sensorion SA is a spin-off of the research team Pathophysiology and Therapy of Vestibular Deficits in Montpellier Neuroscience Institute.